Wednesday, 30 November 2016

Maharashtra govt launches Fight Obesity awareness campaign

Maharashtra government's Medical Education and Drugs Department along with ‘JT Foundation’ has launched "Fight Obesity", an obesity awareness initiative today. Girish Mahajan, minister for medical education and water resources launched this campaign simultaneously across medical colleges in Maharashtra.

The dignitaries at the inaugural function were Dr Jayashree Todkar, Convener of Fight Obesity Campaign & director of JT Foundation, Dr Pravin Shingare, director, Medical Education and Research; Dr Vinayak Kale, Dr Ajay Bhandarwar, head of Department for Laproscopy at J J Hospitals; Dr Nagsen Ramtaje and Dr Saadhik Patel.

Under the leadership of chief minister, Devendra Fadnavis who strives to fight the increasing prevalence of obesity and serious lifestyle diseases associated with it. The state government has formed a task force that will work on the awareness correction, prevention, early diagnosis and treatment of the disease.

As per recent statistics, in a country with 1.25 billion populations, 87.3 million are obese, out of which 12 million have severe obesity. But the growing cases of obesity have led to World Health Organization (WHO) warning India to recognize the threat to life of the Indian population by this disease and take preventive measures to fight obesity. This is also one of the causes for many below the age of 40 suffering from heart attacks and other cardiovascular diseases in India.
To address this high alert situation in the country, a month long campaign that will end on December 29 was also launched. Across 16 medical colleges in various districts of Maharashtra, a BMI testing will be done for medical students, teaching, non-teaching staff and patients at the outpatient department.

"This being a one of a kind initiative in our country, we are glad that we are taking this step to curb a life threatening condition among the current generation. I feel very proud that alon with this inauguration ceremony, every medical educational institute within the state will now have a dedicated obesity clinic. We hope that this month long campaign will help develop a healthier Nation," said Girish Mahajan, minister for medical education, water resources and command area development.

Dr Jayashree Todkar, director, JT Foundation said, "Unfortunately, Obesity is considered a cosmetic problem in our country but it is a health hazard and it is very essential for those who are obese to consult a doctor and learn to maintain a healthier lifestyle. This campaign will help us understand the obese pockets in the state and help in taking remedial measures and provide awareness sessions for them. I would like to thank the State Government to provide us with such a platform, also IDA and AAARO for supporting our initiative.

Monday, 28 November 2016


A seminar on
17th December, 2016

About the Seminar:
The aim of this seminar is to enable the participants to successfully exploit their synthetic and medicinal chemistry expertise with the end goal of discovering compounds suitable for progression into human clinical trials. Lectures from reputed experts from industry and academia will include topics related to Process chemistry, Computer - aided drug discovery (CADD) to support Medicinal chemistry. The seminar will further highlight the current scenario of Intellectual Property in Indian Pharmaceutical R&D and US Patent, general IP Awareness & International filing with an industry perspective. This will help to provide deeper insight into every stage of discovery, from target identification to lead optimization to patent filing and help students explore different career avenues in the field of chemistry.

Who should attend?
* UG/PG/PhD students from Pharmacy and Science field
* Faculty members
* Researchers   

Registration fees:
Rs. 500/- Cash/Cheque in favour of 'Principal, Dr. L. H. Hiranandani College of Pharmacy, Ulhasnagar.

Last date of registration:
15th December, 2016

Eminent Speakers for the Seminar:
1. Dr. Anthony Melvin Crasto, Principal Scientist, Process research, Glenmark Pharmaceuticals Ltd
2. Dr.(Ms) Vibha Bhagat, Asst. Professor, Dept, of Chemistry, Royal College of Arts, Science and Commerce, Mira Road.
3. Dr. S. S. Mahajan, Professor of Pharm. Chem., C. U. Shah College of Pharmacy, Juhu, Mumbai
4. Ms. Madhura Bhide, API IP Team Leader, Cipla Ltd
5.  Mr. Shrikant Podar, Partner, Catalyst Engineers.

CHM Campus, Opp. Ulhasnagar Railway Station, Ulhasnagar-3, Thane, 421003.

Seminar on What do the fresher's lacks for getting better jobs

Friday, 25 November 2016

The Lupin Story_An article by Forbes India

Forbes India Recently published a wonderful article about the growth story of Lupin Pharmaceuticals and the role if the leaders Vinita & Nilesh Gupta in this growth. The article mentions as the duo as The Yin and Yang of Lupin. Putting their diverse management styles to work, Vinita and Nilesh Gupta are dreaming big billions for the pharma major.

They are the winners of Entrepreneur of the year award for 2016 at the Forbes India Leadership Awards 2016.

Final scheme and syllabus for B. Pharm course implemented from 2016-17

Pharmacy Council of India has published Final scheme and syllabus for B. Pharm course implemented from 2016-17. The detailed course can be accessed at

We had recently posted about the Final scheme and syllabus for M. Pharm course at

Indian pharma sector targets $300 billion revenue by 2030

The Indian pharmaceutical sector has the potential to grow to the size of $300 billion by 2030 from the current $15 billion provided it accords high priority on quality and research & development, chief executives of top pharmaceutical companies said.

Speaking at a CEO round table organized by CPhI & P- MEC India in Mumbai, the top executives said Indian firms must begin research on precision medicines to capture the global market.

We must capture the growing biotechnology segment to cash in on the increasing demand for bio-similars,” said D.G. Shah, Secretary General, Indian Pharmaceutical Association (IPA).

Dr Dinesh Dua, MD, Nectar Lifesciences said India must increase its self-reliance for Active Pharmaceutical Ingredients (API) sourcing and has to reduce dependency on China which is dumping API at very low prices making Indian API uncompetitive.

We must address this concern immediately. We urge the government to set up a separate ministry for the pharmaceutical sector to help us achieve the target of $300 billion by 2030.”

They said Indian firms must foster innovation and develop products for the benefit of patients adding that firms must address quality compliance challenges and inculcate quality culture in the organizations to develop high quality medicines for all markets.

For better research and development, the chief executives said the industry must increase collaborations with academia in the form of Indian research institutes and universities, said Mr. Shah of the association.

ICMR-Sun Pharma group to moot drug regulatory, vaccine development overhaul

The group is likely to prioritize a list of diseases that a larger working group, comprising of representation from the drug regulator and pharmaceutical firms, will focus on before the next meeting.

A joint working group (JWG) formed under the aegis of the Indian Council of Medical Research and Sun Pharmaceuticals Ltd, along with experts from International Centre For Genetic Engineering and Biotechnology and All India Institute of Medical Sciences, is planning to propose an overhaul for the drug regulatory system, vaccine development and clinical trials in the country.

The initial ideas mooted for updating the drug regulatory system include political support for the Drug Controller General of India’s regulatory framework, making public the decision for rejection or approval of a drug, maintaining timelines for regulatory approvals, regulatory control on data quality and appointment of specialized reviewers of drug process approval.

The meeting, conducted on Thursday, also involved founder of Sun Pharmaecuticals Dilip Shanghvi and ICMR chief Soumya Swaminathan. The body is expected to reach out to the Drug Controller General of India and other pharmaceutical companies to thrash out more details before making its representation to the government.

The Sun Pharma, through the JWG, will seek consideration of government to initiate development of science-based regulatory systems and appropriate oversight of clinical trials. This is an important aspect of the JWG and would require participation of all stakeholders in academia, pharma industry and the government,” said a statement from Sun Pharma.

The JWG is also likely to prioritize a list of diseases that a larger working group, comprising of representation from the drug regulator and other pharmaceutical companies, will focus on before the next JWG meeting which is scheduled not until another four months.

The idea is to brainstorm and come up with ideas that streamline the drug regulatory process and make it easier for all parties involved. For example, we could look at introducing something like priority vouchers on the lines of the US FDA (Food and Drug Administration) for the Central Drug Standards Control Organization. A systematic process overhaul is something that will make the drug regulatory framework of the country consistent with global standards,” said Altaf Lal, co-chair, JWG and senior advisor, Global Health, Sun Pharma.

The US FDA’s “priority vouchers” incentivize pharmaceutical are incentives to spur the development of new treatments for orhphan diseases–ones that generally do not attract interest due to the cost of development and the lack of market opportunities.

Other proposals discussed include capacity-building in clinical trial facilities in government hospitals, having better animal testing facilities and disease models.

We are also looking at inviting the industry to partner with us–whether it is capacity building for clinical trials or revamping the drug regulatory system,” said Swaminathan.

Online pharmacies see up to 20% jump in sales

Demonetization has neutral impact on sales of medicines after the first week of government's "bold'' announcement, while a substantial part of consumers also switched to ordering medicines through online pharmacies like PharmEasy and 1mg.

While retailers and stockists did not register any dip in sales, e-pharmacies are witnessing a sales spurt of 10-20%, with many consumers stocking up for a month or so, and preponing their medicine purchase. This could also be attributed to the fact that consumers were allowed to buy drugs with banned Rs 500 and Rs 1,000 notes against a prescription. The currencies could also be used at retail stores, as well for cash-on-delivery in online orders.

Retail data collated from stockists across the country showed no reduction in their sales, pharmaceutical research firm AIOCD Awacs said. The survey of 350-plus leading stockists across the country, representing over 2% of the organised pharmaceutical market sales, was done to understand the impact of demonetization on secondary sales in the week ended November 15. Generally, the inventory is two-three days at the retail level, and any reduction in retail (sales) has an immediate impact on stockist sales (secondary trade).

The survey showed no unusual dip in sales, with the fluctuation being within the range, an AIOCD Awacs official said. In small towns and rural areas which deal in only cash, retailers used cheque, bank transfers or part-cash in transactions with stockists.

Initially there was a dip and now there is a spike (in sales). "The (initial) dip was due to confusion over the old currency, but now it's back to normal. The value of transactions are up, while on an average we are adding 10% new consumers every day," Dharmil Sheth, co-founder, PharmEasy told TOI.

Online pharmacies feel that demonetization will have a positive impact going forward. "We saw the sales dip in the first few days, but since then we are seeing a spurt of 20-25% over normal. However, there is also some contribution of the fact that pharmacy is an exempt category and can accept old notes. We expect long-term impact to be positive, since few people go back to cash payments once they learn about the convenience of e-payments," Prashant Tandon, founder and CEO, 1mg said.

In October, the domestic pharma market had witnessed a slightly muted 8.3% growth year-on-year at Rs 10,600 crore. The overall sluggish growth for October constitutes only a minor blip on the market's journey back to its long term average growth rates of 12-13%, analysts say.

Thursday, 24 November 2016

Pharma academic research - Indian patent applications published on 1st July 2016

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.
We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at

Application No
In situ gel drug delivery system and a process for preparing the same
1) Idage Bhaskar Bhairavnath
2) Idage Susheela Bhaskar
3) Bhanudas Shankarrao Kuchekar
Council of Scientific & Industrial Research
Pharmaceutical compositions for the coordinated delivery of naproxen and lansoprazole
1) Vasudha Bakshi
2) Madhu Babu Ananthula
3) Amarachinta Padmanabha Rao
Lalitha College of Pharmacy, Anurag Group of Institutions, Venkatapur (V), Ghatkesar (M),R.R.Dist. Telangana.
Dibenzofuran compounds with antimalarial activity
1) Ethiraj Susithra
2) Durai Pandian Chamundeeswari
3) Shanmugam Meena 
4) Sadras Panchatcharam Thyagarajan
5) Rajasekhar Chekkara
Sri Ramachandra University, Chennai, Tamilnadu
pH triggered drug delivery by metal oxide @graphene/polycaprolactone nanoconjugates
1) Prof. S. Balasubramanian
2) Mr. M. Gajendiran
University of Madras
Pharmaceutical compositions containing surfactant based vesicular delivery systems and preparations thereof
1) Jukanti Raju
2) Smitha Gandra
Not known
Cisplatin polymeric nanoparticle composition and a formulation thereof
1) Maliyakkal Naseer
2) Appadath Beeran Asmy
3) Pai Karkala Sreedhara Ranganath
4) Udupa Nayanabhirama
Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka.
Synergistic pharmaceutical composition for treatment of skin cancer
1) Dr. Verma, S. Rama 
2) Premananda, Sri Pavithra
3) Dr. Narasimhan, Sreevidya
4) Dr. Mehta, Alka
IIT, Madras
Bazedoxifene proliposomal delivery systems and preparations thereof
1) Smitha Gandra
2) Jukanti Raju
3) Karthik Yadav Janga 
4) Sheelam Sharath C Reddy
5) Sakalabattula Naga Sri
Not known
Pharmaceutical compositions comprising fenofibrate and its derivatives for oral delivery
1) Ananthula Madhu Babu
2) Macherla Sharath Chandra Goud
3) Boggarapu Prakash Rao
Not known
Preparation, method and uses of amide benzothiazole derivatives for the treatment of diabetes
1) Mrs. S. Amuthalakshmi
2) Dr. A. Anton Smith
Annamalai University, Chidambaram, Tamilnadu
A novel anticancer property exhibiting compound, Rinoxia b
1) Chinnasamy Arul Vasu
2) Gajendran Babu
University of Madras, Tamilnadu
Pharmaceutical composition of nasal insert comprising cinnarizine, mucoadhesive and drug retardant polymers
1) Dr. S. Bharath
2) Manoj B Kulkarni
M. S. Ramaiah University of Applied Sciences, Bangalore, Karnataka
A herbal formulation for the enhancement of male sexual function
1) Sumanta Kumar Goswami
2) Mankal Nagaraju Patro
3) Mohammed Naseeruddin Inamdar
4) Sarasija Suresh
5) Roopa S. Pai
6) Kshama Devi
Al Ameen College of Pharmacy, Bangalore Karnataka
Pharmaceutical composition, emulgel comprising glucosamine sulphate and permeation enhancer
1) Dr. S. Bharath
2) Patel Nilesh Jasvant Bhai
M. S. Ramaiah University of Applied Sciences, Bangalore, Karnataka
Thiadiazole derivatives with pyrazolidinedione moiety as potential anti-inflammatory and   anti-convulsant agents
1) Suma. B. V
2) Vijayalakshmi
M. S. Ramaiah University of Applied Sciences, Bangalore, Karnataka

Tuesday, 22 November 2016

1000 Jan Aushadhi stores to come-up in pharmacy colleges by March 2017

To increase availability of generic medicines at affordable prices and to promote Jan Aushadhi Scheme, the Pharmacy Council of India (PCI) encourages colleges to establish Jan Aushadhi stores in their premises. This will serve both the purpose of requirement of quality medicine at affordable price as well as the requirement of practical training to the student pharmacists under the provisions of  'the education regulations, 1991' and 'the bachelor of pharmacy course regulation, 2014'.

The PCI will extend support by way of pursuance with regulatory bodies like BPPI and state drug control departments for the issuance of licenses to the colleges. The council has also directed the state pharmacy council to provide guidance to the colleges in their respective states.

Dr B Suresh, president of PCI says, “PCI is encouraging pharmacy colleges to establish Jan Aushadhi store in their premises. After issuing the circular of this initiative by the council, many institutes have shown interest in the opening the store. With this step around 1000 more Jan Aushadhi store will come-up by March 2017. We have also asked the state pharmacy council to take-up the matter of registration and even they can open a store in the council’s premises

The council is working with ministry of chemical and fertilizers to promote Jan Aushadhi Scheme by establishing Jan Aushadhi stores in approved pharma colleges across the country. There is a statutory requirement for students to undergo practical training in pharmacy practice in hospital or community pharmacy. Hence by becoming a partner to Prime Minister's Jan Aushadhi Yojna (PMJAY), pharmacy institutions will fulfil the requirement.

The Jan Aushadhi Scheme is a direct market intervention scheme of the department of pharmaceuticals, with an aim to make available quality generic medicines to all at affordable prices through Jan Aushadhi Store (JAS) opened in each district of the states. It was first launched in 2008 to provide quality medicines at affordable prices to the economically weaker sections of the society. The first JAS was opened at Amritsar Civil Hospital in 2008.

Monday, 21 November 2016

Final scheme & Syllabus for M. Pharm course implemented from 2016-17 academic session

Pharmacy Council of India (PCI) has published final scheme & Syllabus for M. Pharm course implemented from 2016-17 academic sessions. This syllabus is based on notification in the gazette of India no. 362, dated December 11th 2014.

The full text syllabus is available at

The new M Pharm syllabus will be more of practical oriented rather than theory and the students will have an option to work with the industry and get a practical experience along with the stipend.

The new syllabus is all set and will appear on the PCI website since November 17, 2016. The council has assured that the new syllabus will benefit the students as well as the industry.

Dr B Suresh, president of PCI says, "The new syllabus of M Pharm is a new approach to postgraduate education. The two-year course will include a theory based education, in the first year and in the second year we have included non thesis as an option to research project. So the student can opt either for a non thesis or research project for one year. The benefit of non thesis is that the student will get a real practical experience during their course duration itself and the industry can also utilise the human resources and get the best of it."

The PCI will also have a tie-up with the industry for the recruitment of the M Pharm students in the coming days. Along with DCGI, the council is planning a meeting with the industry associations regarding the non thesis option included in the M Pharm syllabus. It will also request the industry to provide stipends to the students so that they are not exploited and later on if the companies want they can also recruit them.

We have made a committee which will be working on the tie-ups with the industry. We will be meeting the industry associations like IDMA, IPA, CIPI etc. in the month of January or February”, said Dr Suresh.

Friday, 18 November 2016

International Conference on Challenges in Drug Discovery and Delivery (ICCD3 - 2017)

Department of Pharmacy, BITS-Pilani would like to invite you to the International Conference on Challenges in Drug Discovery and Delivery (ICCD3) to be held in Birla Institute of Technology and Science Pilani, Rajasthan, India in March 2-4, 2017. The conference will have invited lectures from eminent scientists in the field from around the globe. Further, during this three-day event, the participants will have opportunities to meet network colleagues and present their latest research findings as oral short communications / posters. The future networking opportunities between the research groups will be also discussed.

Call for Abstracts:
Authors are invited to submit their significant original and unpublished contributions on the topics listed below, but certainly not limited to: 
·         Computer Aided Drug Design
·         Combinatorial Chemistry
·         Phytopharmaceutical/Natural Product Chemistry
·         Pharmacology and Pharmaco-therapeutics
·         Preclinical and Clinical studies
·         Proteomics and Bioinformatics
·         ADMET and PK/PD modeling
·         Quality Assurance and Regulatory Affairs
·         Pharmaceutical Analysis
·         Advanced Drug Delivery Systems (including Gene Delivery)
·         Pharmaceutical Nanotechnology (including Nanobiotechnology)
·          Herbal Drug Technology

Last date for Abstract submission: December 15th, 2016

Notification of acceptance: December 20th, 2016

Last date for registration: December 30th, 2016

Conference dates: March 2-4, 2017